RAS and Other Molecular Targets in Pancreatic Cancer: The Next Wave Is Coming.

Abstract excerpt

OPINION STATEMENT: Since the discovery of oncogenes in the 1970s, cancer doctors and researchers alike have understood the promise of discovering drugs to block the dominantly acting function of mutated signaling proteins in cancer. This promise was delivered, first slowly, with early signals inhibiting HER2 and BCR-Abl in the 1990s and 2000s, and then quickly, with kinase inhibitors being approved hand over fist...

Topics

Join the communities discussing this publication.

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Mutation
• Pancreatic Neoplasms
• Proto-Oncogene Proteins p21(ras)